RATIONALE: Antibodies to influenza hemagglutinin are the primary correlate of protection against infection. The strength and persistence of this immune response influences viral evolution and consequently the nature of influenza epidemics. However, the durability and immune determinants of induction of humoral immunity after primary influenza infection remain unclear. OBJECTIVES: The spread of a novel H1N1 (A[H1N1]pdm09) virus in 2009 through an unexposed population offered a natural experiment to assess the nature and longevity of humoral immunity after a single primary influenza infection. METHODS: We followed A(H1N1)pdm09-seronegative adults through two influenza seasons (2009-2011) as they developed A(H1N1)pdm09 influenza infection or were vaccinated. Antibodies to A(H1N1)pdm09 virus were measured by hemagglutination-inhibition assay in individuals with paired serum samples collected preinfection and postinfection or vaccination to assess durability of humoral immunity. Preexisting A(H1N1)pdm09-specific multicytokine-secreting CD4 and CD8 T cells were quantified by multiparameter flow cytometry to test the hypothesis that higher frequencies of CD4(+) T-cell responses predict stronger antibody induction after infection or vaccination. MEASUREMENTS AND MAIN RESULTS: Antibodies induced by natural infection persisted at constant high titer for a minimum of approximately 15 months. Contrary to our initial hypothesis, the fold increase in A(H1N1)pdm09-specific antibody titer after infection was inversely correlated to the frequency of preexisting circulating A(H1N1)pdm09-specific CD4(+)IL-2(+)IFN-γ(-)TNF-α(-) T cells (r = -0.4122; P = 0.03). CONCLUSIONS: The longevity of protective humoral immunity after influenza infection has important implications for influenza transmission dynamics and vaccination policy, and identification of its predictive cellular immune correlate could guide vaccine development and evaluation.
RATIONALE: Antibodies to influenza hemagglutinin are the primary correlate of protection against infection. The strength and persistence of this immune response influences viral evolution and consequently the nature of influenza epidemics. However, the durability and immune determinants of induction of humoral immunity after primary influenza infection remain unclear. OBJECTIVES: The spread of a novel H1N1 (A[H1N1]pdm09) virus in 2009 through an unexposed population offered a natural experiment to assess the nature and longevity of humoral immunity after a single primary influenza infection. METHODS: We followed A(H1N1)pdm09-seronegative adults through two influenza seasons (2009-2011) as they developed A(H1N1)pdm09 influenza infection or were vaccinated. Antibodies to A(H1N1)pdm09 virus were measured by hemagglutination-inhibition assay in individuals with paired serum samples collected preinfection and postinfection or vaccination to assess durability of humoral immunity. Preexisting A(H1N1)pdm09-specific multicytokine-secreting CD4 and CD8 T cells were quantified by multiparameter flow cytometry to test the hypothesis that higher frequencies of CD4(+) T-cell responses predict stronger antibody induction after infection or vaccination. MEASUREMENTS AND MAIN RESULTS: Antibodies induced by natural infection persisted at constant high titer for a minimum of approximately 15 months. Contrary to our initial hypothesis, the fold increase in A(H1N1)pdm09-specific antibody titer after infection was inversely correlated to the frequency of preexisting circulating A(H1N1)pdm09-specific CD4(+)IL-2(+)IFN-γ(-)TNF-α(-) T cells (r = -0.4122; P = 0.03). CONCLUSIONS: The longevity of protective humoral immunity after influenza infection has important implications for influenza transmission dynamics and vaccination policy, and identification of its predictive cellular immune correlate could guide vaccine development and evaluation.
Entities:
Keywords:
T cells; antibodies; epidemiology; immunology; pandemic influenza
Authors: Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu Journal: Nat Med Date: 2012-01-29 Impact factor: 53.440
Authors: W E Adamson; E C McGregor; K Kavanagh; J McMenamin; S McDonagh; P J Molyneaux; K E Templeton; W F Carman Journal: J Clin Virol Date: 2011-09-15 Impact factor: 3.168
Authors: Kwok-Hung Chan; Kelvin K W To; Ivan F N Hung; Anna J X Zhang; Jasper F W Chan; Vincent C C Cheng; Herman Tse; Xiao-Yan Che; Honglin Chen; Kwok-Yung Yuen Journal: Clin Vaccine Immunol Date: 2011-03-16
Authors: Yan Tan; Pablo Tamayo; Helder Nakaya; Bali Pulendran; Jill P Mesirov; W Nicholas Haining Journal: Eur J Immunol Date: 2013-11-29 Impact factor: 5.532
Authors: Matthew S Miller; Thomas J Gardner; Florian Krammer; Lauren C Aguado; Domenico Tortorella; Christopher F Basler; Peter Palese Journal: Sci Transl Med Date: 2013-08-14 Impact factor: 17.956
Authors: Beatriz León; John E Bradley; Frances E Lund; Troy D Randall; André Ballesteros-Tato Journal: Nat Commun Date: 2014-03-17 Impact factor: 14.919
Authors: Hana Hakim; Kim J Allison; Lee-Ann Van de Velde; Li Tang; Yilun Sun; Patricia M Flynn; Jonathan A McCullers Journal: Vaccine Date: 2016-04-26 Impact factor: 3.641
Authors: Gro Tunheim; Ida Laake; Anna Hayman Robertson; Kristian Waalen; Olav Hungnes; Lisbeth M Naess; Rebecca J Cox; Siri Mjaaland; Lill Trogstad Journal: Influenza Other Respir Viruses Date: 2019-01-01 Impact factor: 4.380